Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone.

A Leal1, D Rosillon, A Mehnert

  • 1SGS-Biopharma, B-1301 Wavre, Belgium.

Pharmacoepidemiology and Drug Safety
|September 24, 2004
PubMed
Summary

Long-acting risperidone significantly reduced hospitalizations and healthcare resource use in patients with schizophrenia and schizoaffective disorder. These findings suggest potential for decreased healthcare costs with this treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tardive dyskinesia versus tardive syndrome. What is in a name?

Parkinsonism & related disorders·2025
Same author

Return to work and work productivity in patients with breast cancer: a longitudinal study (abridged secondary publication).

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Calculation of vessel pulse wave velocities in retinal vein segments within the optic disc centre.

Scientific reports·2024
Same author

Correlation between retinal vein pulse amplitude, estimated intracranial pressure, and postural change.

NPJ microgravity·2023
Same author

Effects and mechanotransduction pathways of therapeutic ultrasound on healthy and osteoarthritic chondrocytes: a systematic review of in vitro studies.

Osteoarthritis and cartilage·2022
Same author

Der Urologe. Ausg. A·2021

Area of Science:

  • Psychiatry
  • Pharmacoeconomics

Background:

  • Schizophrenia and schizoaffective disorder impose substantial healthcare costs, primarily driven by high hospitalization rates.
  • This study investigated healthcare resource utilization in patients with these conditions during treatment with long-acting risperidone.

Purpose of the Study:

  • To assess the impact of long-acting risperidone on healthcare resource use in patients with schizophrenia and schizoaffective disorder.
  • To evaluate changes in hospitalization rates, duration, and outpatient service utilization.

Main Methods:

  • A 1-year, open-label study involving 397 patients (24% inpatients, 76% outpatients) with stable schizophrenia or schizoaffective disorder.
  • Patients transitioned from oral risperidone to intramuscular long-acting risperidone (25 or 50 mg every 2 weeks).

Related Experiment Videos

  • Healthcare resource use was assessed at baseline and every 12 weeks over the study period.

    • Main Results:

    • Hospitalization rates decreased significantly from 38% pre-treatment to 12% in the final 12 weeks.
    • Mean hospitalization length was reduced, with 71% of initially hospitalized patients discharged during treatment.
    • Partial hospitalization and outpatient consultation rates also showed significant reductions.

    Conclusions:

    • Long-acting risperidone treatment significantly reduces healthcare resource use in patients with stable schizophrenia or schizoaffective disorder.
    • The observed reductions in resource utilization strongly indicate a potential decrease in overall healthcare costs.